Open AccessThe impact of an URAT1 polymorphism on the losartan treatment of hypertension and hyperuricemia
Author(s) -
Wu Liting,
Fan Yingchao,
Wang Yuan,
Li Zhumeng,
Mao Delong,
Zhuang Wenfang
Publication year - 2021
Publication title -
journal of clinical laboratory analysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.536
H-Index - 50
eISSN - 1098-2825
pISSN - 0887-8013
DOI - 10.1002/jcla.23949
Subject(s) - hyperuricemia , uricosuric , losartan , medicine , endocrinology , single nucleotide polymorphism , creatine , snp , slco1b1 , uric acid , angiotensin ii , genotype , gene , biology , genetics , receptor
Abstract Background This study was designed to evaluate the impact of polymorphisms in the urate transporter 1 ( URAT1 ) gene on the uricosuric action of losartan therapy in hypertensive patients suffering from hyperuricemia. Methods A MassARRAY approach was used to detect single nucleotide polymorphism (SNP) loci in the URAT1 and CYP2C9 genes (16 and 2 loci, respectively) in 111 patients with hypertension and hyperuricemia taking losartan and in 121 healthy controls. In addition, we compared serum urate (SUA) levels and other key clinical biochemistry indices between these two patient groups. Results We detected significant differences between the two patient groups with respect to age, SUA, urea, creatine, triglycerides, high‐density lipoprotein, low‐density lipoprotein, and fasting plasma glucose ( all p < 0.05). In addition, we found that hypertensive patients with hyperuricemia were more likely to exhibit the rs3825016(C/T) (36.9% vs 21.5%, p = 0.03), and we determined that a 2‐week treatment course with losartan was associated with significant decreases in SUA values ( p < 0.001). Conclusion Our findings indicate that the URAT1 rs3825016 polymorphism may influence the uricosuric action of losartan.